# DESCRIPTION

## FIELD OF THE INVENTION

- introduce angiogenesis inhibition peptides

## BACKGROUND OF THE INVENTION

- define angiogenesis and vasculogenesis
- describe role of angiogenesis in tumor growth
- explain regulation of angiogenesis
- introduce chemokines and their functions
- describe CXC chemokine family
- explain angiostatic and angiogenic effects of CXCL10
- discuss CXCR3 receptor and its isoforms
- describe CXCL10's effects on endothelial cells
- discuss CXCL10's role in wound healing
- highlight need for improved therapeutics
- summarize current understanding of CXCL10

## SUMMARY OF THE INVENTION

- introduce peptides with CXCR3 potency
- describe treatment for tumorogenic diseases
- describe treatment for chronic wounds
- highlight non-toxic formulations
- introduce IP-10dp peptide
- describe IP-10dp's effects on endothelial cells
- outline uses of IP-10dp and derivatives

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

- define effective amount of composition
- describe polynucleotides of the invention
- explain hybridizable polynucleotides
- describe recombinant vectors of the invention
- outline transformants of the invention
- introduce methods for transforming hosts
- describe production of peptides by culturing transformants
- introduce chemokine derived peptides used in embodiments
- describe molecular modeling of IP-10 and IP-10dp
- explain topology of CXCL10 and inhibitory function
- describe analysis of IP-10 full length sequence
- outline experimental methods for evaluating efficacy of peptides
- describe cell cultures and peptide synthesis
- outline siRNA down regulation of CXCR3
- describe biotin labeling and flow cytometry
- introduce experimental results and data analysis
- describe experimental setup for scratch assays
- report results of scratch assays
- describe experimental setup for tube formation assays
- report results of tube formation assays
- describe experimental setup for tube dissociation assays
- report results of tube dissociation assays
- describe experimental setup for CXCR3 signaling assays
- report results of CXCR3 signaling assays
- describe experimental setup for cAMP production assays
- report results of cAMP production assays
- describe experimental setup for PKA activity assays
- report results of PKA activity assays
- describe prior research on CXCR3-activation of PKA
- motivate experiment to study IP-10dp effect on m-calpain
- describe experimental design for studying calpain activity
- present results of calpain activity experiment
- describe experiment 11 to study IP-10dp inhibition of vessel growth
- describe experimental design for Matrigel assay
- present results of Matrigel assay
- describe experiment to verify IP-10dp regression of newly formed vessels
- present results of vessel regression experiment
- summarize results of experiments 11 and 12
- describe experiment 12 to study relationship of CXCR3 ligands to wound repair
- describe wounding assay and tissue analysis
- present results of wound repair experiment
- describe experiment 13 to assess tensile strength of regenerated wound tissue
- present results of tensile strength experiment
- describe experiment 14 to confirm delay in dermal wound healing in CXCR3-/- mice
- describe skin maturation
- detail experiment 15
- describe experiment 16
- detail IP-9AS mice generation
- describe wound creation and analysis
- detail histological scoring system
- describe collagen content and alignment analysis
- detail immunohistochemical analysis
- summarize experiment 16 results
- describe experiment 17
- detail tensile strength measurement
- summarize experiment 17 results
- discuss therapeutic implications
- conclude and discuss scope of invention

